Leflunomide exposure through second trimester of pregnancy: A case report.

Leflunomide is a commonly used disease modifying antirheumatic agent. However, its use is contraindicated in pregnancy. The American College of Rheumatology (ACR) guidelines recommend discontinuing Leflunomide at least 24 months before conception. If a woman is found to be pregnant while on Leflunomide, ACR suggests close monitoring and cholestyramine washout. We describe a case of a patient with a history of juvenile idiopathic arthritis who was on Leflunomide throughout the first and second trimester of her pregnancy. A cholestyramine washout regimen was started but not completed. The patient was induced at 37 weeks of gestation due to non-reassuring fetal heart rate. She ultimately delivered a healthy baby via emergency cesarian section. © 2023 The Authors. Birth Defects Research published by Wiley Periodicals LLC.

Citation

Rawan Alothman, James Yeung, Elizabeth Waterman, Christa Lepik, Neda Amiri. Leflunomide exposure through second trimester of pregnancy: A case report. Birth defects research. 2023 Oct 01;115(16):1566-1569

Mesh Tags

Substances

PMID: 37462087

search → result